CN1832965B - 内皮细胞特异性抗体及其用途 - Google Patents

内皮细胞特异性抗体及其用途 Download PDF

Info

Publication number
CN1832965B
CN1832965B CN2004800121265A CN200480012126A CN1832965B CN 1832965 B CN1832965 B CN 1832965B CN 2004800121265 A CN2004800121265 A CN 2004800121265A CN 200480012126 A CN200480012126 A CN 200480012126A CN 1832965 B CN1832965 B CN 1832965B
Authority
CN
China
Prior art keywords
antibody
cells
fragment
tem1
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800121265A
Other languages
English (en)
Chinese (zh)
Other versions
CN1832965A (zh
Inventor
B·泰彻尔
B·罗伯茨
片冈之郎
田原知幸
本间央之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Genzyme Corp
Original Assignee
Kirin Brewery Co Ltd
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32966870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1832965(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Brewery Co Ltd, Genzyme Corp filed Critical Kirin Brewery Co Ltd
Publication of CN1832965A publication Critical patent/CN1832965A/zh
Application granted granted Critical
Publication of CN1832965B publication Critical patent/CN1832965B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2004800121265A 2003-03-04 2004-03-04 内皮细胞特异性抗体及其用途 Expired - Lifetime CN1832965B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US45185203P 2003-03-04 2003-03-04
US45185603P 2003-03-04 2003-03-04
US60/451,856 2003-03-04
US60/451,852 2003-03-04
US45246903P 2003-03-06 2003-03-06
US60/452,469 2003-03-06
US46380103P 2003-04-18 2003-04-18
US60/463,801 2003-04-18
US46530403P 2003-04-24 2003-04-24
US60/465,304 2003-04-24
US47117703P 2003-05-16 2003-05-16
US60/471,177 2003-05-16
PCT/US2004/006719 WO2004078942A2 (en) 2003-03-04 2004-03-04 Endothelial cell specific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN1832965A CN1832965A (zh) 2006-09-13
CN1832965B true CN1832965B (zh) 2011-03-02

Family

ID=32966870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800121265A Expired - Lifetime CN1832965B (zh) 2003-03-04 2004-03-04 内皮细胞特异性抗体及其用途

Country Status (11)

Country Link
US (1) US20070020271A1 (https=)
EP (3) EP2267031A1 (https=)
JP (2) JP4928259B2 (https=)
KR (1) KR20060003860A (https=)
CN (1) CN1832965B (https=)
AT (1) ATE493440T1 (https=)
AU (1) AU2004217442A1 (https=)
BR (1) BRPI0409575A (https=)
CA (1) CA2518490A1 (https=)
DE (1) DE602004030764D1 (https=)
WO (1) WO2004078942A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029045A2 (en) * 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
AU2005311660B2 (en) * 2004-12-03 2011-07-07 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
JP2008538700A (ja) * 2005-04-22 2008-11-06 モルフォテック、インク． 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
WO2008057632A1 (en) 2006-11-09 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
SI2137217T1 (sl) * 2007-04-05 2014-07-31 Morphotek, Inc. Postopki za inhibiranje vezave endosialina na ligande
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
US20130305396A1 (en) * 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
JP2014524902A (ja) 2011-06-14 2014-09-25 アメリカ合衆国 Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
CN104931697B (zh) * 2015-05-28 2017-03-01 上海交通大学医学院附属仁济医院 Cd248+cd8+t细胞亚群在人升主动脉瘤病变过程中的作用
CN106591207B (zh) * 2016-12-07 2019-10-29 南昌大学 用于表达aif及整合有aif的重组单链抗体的菌株及该菌株的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU688880B2 (en) * 1994-03-08 1998-03-19 Ludwig Institute For Cancer Research Recombinant humanized anti-FB5 antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
CA2416732C (en) * 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AU2002258543B2 (en) * 2001-04-11 2008-05-22 The Johns Hopkins University Endothelial cell expression patterns

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof

Also Published As

Publication number Publication date
DE602004030764D1 (de) 2011-02-10
EP2264073A1 (en) 2010-12-22
EP1599503A2 (en) 2005-11-30
CA2518490A1 (en) 2004-09-16
JP2011052002A (ja) 2011-03-17
CN1832965A (zh) 2006-09-13
EP2267031A1 (en) 2010-12-29
WO2004078942A2 (en) 2004-09-16
BRPI0409575A (pt) 2006-04-18
JP4928259B2 (ja) 2012-05-09
AU2004217442A1 (en) 2004-09-16
US20070020271A1 (en) 2007-01-25
ATE493440T1 (de) 2011-01-15
WO2004078942A3 (en) 2005-04-21
JP2006521388A (ja) 2006-09-21
EP1599503B1 (en) 2010-12-29
KR20060003860A (ko) 2006-01-11

Similar Documents

Publication Publication Date Title
US20250282888A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP2011052002A (ja) 内皮細胞特異的抗体およびその使用
JP6385277B2 (ja) 癌治療のための抗ｃｅａｃａｍ１組換え型抗体
US20210155700A1 (en) ANTI-DEspR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
KR101818741B1 (ko) 암 치료용 모노클로날 항체
JP5328156B2 (ja) オンコスタチンｍレセプターに対する抗体
MX2010008199A (es) Composiciones y metodos para el tratamiento de tumores de origen hematopoyetico.
RU2365382C2 (ru) Композиции и способы для регуляции развития сосудов
WO2007098575A1 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
WO2003047623A1 (en) Treatment of prostate cancer by inhibitors of ncam2
JP2017505107A (ja) Ｃｃｒ９に対する抗体およびその用途
WO2006017759A2 (en) Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2005086713A2 (en) Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006029045A2 (en) Endothelial cell specific antibodies and uses thereof
JP2020511140A (ja) 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物
US20250179190A1 (en) Integrin Alpha10 Antibody
US20060058257A1 (en) Influencing angiogenesis using CD66a
HK1105434A (en) Cancerous disease modifying antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20110302

CX01 Expiry of patent term